Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults
The DOI matches its Crossref record; 37 of the 51 references it cites were found in a registry or an index.
Abstract
CONTEXT: The gastrointestinal peptide hormone, peptide YY(3-36) (PYY(3-36)), is implicated to be a postprandial satiety factor. OBJECTIVE: The aim of this study is to assess the safety, tolerability, and efficacy of intranasal PYY(3-36) to induce weight loss in obese patients. DESIGN: The study was designed as a randomized, 2-wk, single-blind placebo run-in followed by a 12-wk double-blind, placebo-controlled treatment period. SETTING: The study was set within a private and institutional practice. PATIENTS: A total of 133 obese patients (body mass index, 30-43 kg/m(2); age, 18-65 yr) participated in the study. INTERVENTION: Placebo or 200- or 600-microg PYY(3-36) was administered as an intranasal spray 20 min before breakfast, lunch, and dinner in conjunction with a hypocaloric diet and exercise. MAIN OUTCOME MEASURE: Body weight was the main outcome measure. RESULTS: The number of patients completing 12 wk on the drug was 38 of 43 (88%), 31 of 44 (70%), and 12 of 46 (26%) for placebo, 200 microg three times a day (t.i.d.) and 600 microg t.i.d., respectively. In the 600 microg t.i.d. group, 27 of 46 (59%) patients discontinued due to nausea and vomiting. Among all randomized patients who took at least one drug dose and had a postbaseline measurement, the mean body weight change from baseline was -2.8, -3.7, and -1.4 kg for placebo, 200 and 600 microg, respectively. The least squares mean difference (95% confidence interval) between placebo and 200 microg was -0.9 (-2.6, 0.7) kg (P = 0.251). A difference of 2.11 kg was sought. No meaningful inference can be drawn from the few patients who completed the study on 600 microg. CONCLUSIONS: Intranasal PYY(3-36) as administered at these intervention doses and preprandial timing is not efficacious in inducing weight loss in obese patients after 12 wk of treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies with PYY agonists administered intravenously have shown reduction in food intake with increased satiety [92, 93], however, a nasal PYY agonist showed minimal efficacy with poor tolerability [94].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [94]
In the citing paper
“Some PYY agents evaluated for monotherapy of obesity resulted in unacceptable nausea and vomiting and limited weight reduction [165,168].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [168]
Citations
Cites
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
Sniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Human distribution and release of a putative new gut hormone, peptide YY
Adrian, T. E., Ferri, G.-L., Bacarese-Hamilton, A. J., Fuessl, H. S., Polak, J. M., & Bloom, S. R. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90211-2 · Cited by 1,065
Roux, C. W. L., Aylwin, S. J. B., Batterham, R. L., Borg, C. M., Coyle, F., Prasad, V., Shurey, S., Ghatei, M. A., Patel, A. G., & Bloom, S. R. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000183349.16877.84 · Cited by 985
Transport of drugs from the nasal cavity to the central nervous system
Illum, L. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00087-7 · Cited by 907
Tatemoto, K., & Mutt, V. (1980) · Nature · doi:10.1038/285417a0 · Cited by 659
Attenuated Peptide YY Release in Obese Subjects Is Associated with Reduced Satiety
le Roux, C. W., Batterham, R. L., Aylwin, S. J. B., Patterson, M., Borg, C. M., Wynne, K. J., Kent, A., Vincent, R. P., Gardiner, J., Ghatei, M. A., et al. (2006) · Endocrinology · doi:10.1210/en.2005-0972 · Cited by 552
The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats
Koda, S., Date, Y., Murakami, N., Shimbara, T., Hanada, T., Toshinai, K., Niijima, A., Furuya, M., Inomata, N., Osuye, K., et al. (2005) · Endocrinology · doi:10.1210/en.2004-1266 · Cited by 431
Korner, J., Bessler, M., Cirilo, L. J., Conwell, I. M., Daud, A., Restuccia, N. L., & Wardlaw, S. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1076 · Cited by 417
Effect of Peptide YY3–36 on Food Intake in Humans
Degen, L., Oesch, S., Casanova, M., Graf, S., Ketterer, S., Drewe, J., & Beglinger, C. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.09.001 · Cited by 366
Grandt, D., Schimiczek, M., Beglinger, C., Layer, P., Goebell, H., Eysselein, V. E., & Reeve, J. R. (1994) · Regulatory Peptides · doi:10.1016/0167-0115(94)90204-6 · Cited by 364
Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV
Mentlein, R., Dahms, P., Grandt, D., & Krüger, R. (1993) · Regulatory Peptides · doi:10.1016/0167-0115(93)90435-b · Cited by 349
Borg, C. M., le Roux, C. W., Ghatei, M. A., Bloom, S. R., Patel, A. G., & Aylwin, S. J. B. (2006) · British Journal of Surgery · doi:10.1002/bjs.5227 · Cited by 318
Broberger, C., Landry, M., Wong, H., Walsh, J. N., & Hökfelt, T. (1997) · Neuroendocrinology · doi:10.1159/000127265 · Cited by 298
Does gut hormone PYY3–36 decrease food intake in rodents?
Tschöp, M., Castañeda, T. R., Joost, H. G., Thöne-Reineke, C., Ortmann, S., Klaus, S., Hagan, M. M., Chandler, P. C., Oswald, K. D., Benoit, S. C., et al. (2004) · Nature · doi:10.1038/nature02665 · Cited by 292
Stock, S., Leichner, P., Wong, A. C. K., Ghatei, M. A., Kieffer, T. J., Bloom, S. R., & Chanoine, J.-P. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1251 · Cited by 281
Peptide YY3–36Inhibits Food Intake in Mice through a Melanocortin-4 Receptor-Independent Mechanism
Halatchev, I. G., Ellacott, K. L. J., Fan, W., & Cone, R. D. (2004) · Endocrinology · doi:10.1210/en.2003-1754 · Cited by 237
Effects of PYY[3–36] in rodent models of diabetes and obesity
Pittner, R. A., Moore, C. X., Bhavsar, S. P., Gedulin, B. R., Smith, P. A., Jodka, C. M., Parkes, D. G., Paterniti, J. R., Srivastava, V. P., & Young, A. A. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802696 · Cited by 219
Nasal Route for Direct Delivery of Solutes to the Central Nervous System: Fact or Fiction?
Mathison, S., Nagilla, R., & Kompella, U. B. (1998) · Journal of Drug Targeting · doi:10.3109/10611869808997870 · Cited by 200
Peripheral administration of PYY3–36 produces conditioned taste aversion in mice
Halatchev, I. G., & Cone, R. D. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.02.003 · Cited by 191
Moran, T. H., Smedh, U., Kinzig, K. P., Scott, K. A., Knipp, S., & Ladenheim, E. E. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00535.2004 · Cited by 189
Acuna, C., & van den Pol, A. N. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2552-05.2005 · Cited by 133
PYY3‐36 as an anti‐obesity drug target
Boggiano, M. M., Chandler-Laney, P. C., Oswald, K. D., Rodgers, R. J., Blundell, J. E., Ishii, Y., Beattie, A. H., Holch, P., Allison, D. B., Schindler, M., et al. (2005) · Obesity Reviews · doi:10.1111/j.1467-789x.2005.00218.x · Cited by 131
Acuna-Goycolea, C., Tamamaki, N., Yanagawa, Y., Obata, K., & van den Pol, A. N. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1008-05.2005 · Cited by 125
BIIE0246, a potent and highly selective non‐peptide neuropeptide Y Y 2 receptor antagonist
Dumont, Y., Cadieux, A., Doods, H. N., Pheng, L. H., Abounader, R., Hamel, É., Jacques, D., Regoli, D. C., & Quirion, R. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703162 · Cited by 121
Riediger, T., Bothe, C., Becskei, C., & Lutz, T. A. (2004) · Neuroendocrinology · doi:10.1159/000079842 · Cited by 119
Koegler, F. H., Enriori, P. J., Billes, S. K., Takahashi, D. L., Martin, M. S., Clark, R. L., Evans, A. E., Grove, K. L., Cameron, J. L., & Cowley, M. A. (2005) · Diabetes · doi:10.2337/diabetes.54.11.3198 · Cited by 98
Wyss, P., Stricker‐Krongrad, A., Brunner, L., Miller, J. W., Crossthwaite, A. J., Whitebread, S., & Criscione, L. (1998) · Regulatory Peptides · doi:10.1016/s0167-0115(98)00089-5 · Cited by 89
Ghamari‐Langroudi, M., Colmers, W. F., & Cone, R. D. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.08.003 · Cited by 84
Braiding patterns on an inclined plane
Mertens, K., Putkaradze, V., & Vorobieff, P. V. (2004) · Nature · doi:10.1038/430165a · Cited by 56
Enhancement of feeding suppression by PYY3-36 in rats with area postrema ablations
Cox, J. E., & Randich, A. (2004) · Peptides · doi:10.1016/j.peptides.2004.03.003 · Cited by 55
Bonaventure, P., Nepomuceno, D. H., Mazur, C., Lord, B., Rudolph, D. A., Jablonowski, J. A., Carruthers, N. I., & Lovenberg, T. W. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060459 · Cited by 53
Lower mean weight after 14 days intravenous administration peptide YY3–36 (PYY3–36) in rabbits
Sileno, A. P., Brandt, G., Spann, B. M., & Quay, S. C. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0803067 · Cited by 44
Patriti, A., Facchiano, E., GULL, N., Aisa, M. C., & Annetti, C. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000250941.44516.b3 · Cited by 43
Jacques, D., Dumont, Y., Fournier, A., & Quirion, R. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00639-2 · Cited by 42
Physiology: Does gut hormone PYY3–36 decrease food intake in rodents?
Tschöp, M., Castañeda, T. R., Joost, H., Thöne‐Reineke, C., Ortmann, S., Klaus, S., Hagan, M., Chandler-Laney, P. C., Oswald, K. D., Benoit, S. C., et al. (2004) · Nature Cell Biology · doi:10.1038/nature02665a · Cited by 18
Research works printed but not linked: 2
- Batterham, 2003, Inhibition of food intake in obese subjects by peptide YY3–36., N Engl J Med, 349, 941
- Wyss, 1998, 76, 363
Cited by
Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity
Silva, A. D., & Bloom, S. R. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.1.10 · Cited by 373
“Administration of intra-nasal PYY3-36 was tested in obese human subjects as a weight-loss treatment, but encountered significant problems with nausea and vomiting.(48) In this study, placebo or intra-nasal PYY3-36 was administered at a dose of 200 mcg 3 times daily or 600 mcg 3 times daily for 12 weeks.”
BackgroundMethodWhat is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“Studies with PYY agonists administered intravenously have shown reduction in food intake with increased satiety [92, 93], however, a nasal PYY agonist showed minimal ef fi cacy with poor tolerability [94].”
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
“Intranasal administration of 200 or 600 mg PYY(3e36) three times daily before each meal for 12 weeks in human subjects with obesity failed to exhibit either a dose-dependent or meaningful reduction in body weight [110].”
BackgroundBenedict, C., Kern, W., Schultes, B., Born, J., & Hallschmid, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2606 · Cited by 296
Bessesen, D. H. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0520 · Cited by 257
“Recent data using intranasal administration have produced mixedresults (42).”
Background
Metadata
- Authors
- Gantz, I., Erondu, N., Mallick, M., Musser, B., Krishna, R., Tanaka, W. K., Snyder, K., Stevens, C., Stroh, M. A., Zhu, H., Wagner, J. A., MacNeil, D. J., Heymsfield, S. B., & Amatruda, J. M.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Gantz, Ira
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-05-01
- Volume
- 92
- Issue
- 5
- Pages
- 1754-1757
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2118965081
- Cited by
- 163
- References
- 51
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 10 · 2020: 5 · 2019: 5 · 2018: 4 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 12 · 2013: 10 · 2012: 13
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- PYY3-36, intranasal administration, weight loss, obesity, satiety hormones, hypocaloric diet, physical activity, nausea and vomiting, drug safety and tolerability, appetite regulation, gastrointestinal hormones, obesity pharmacotherapy, dose comparison, treatment discontinuation
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Aged, Body Weight, Diet, Reducing, Dose-Response Relationship, Drug, Double-Blind Method, Exercise Therapy, Female, Humans, Male, Middle Aged, Obesity, Peptide Fragments, Weight Loss, Body Mass Index, Treatment Outcome, Peptide YY
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.